SA515361104B1 - مشتقات بيريدين-4-يل - Google Patents

مشتقات بيريدين-4-يل Download PDF

Info

Publication number
SA515361104B1
SA515361104B1 SA515361104A SA515361104A SA515361104B1 SA 515361104 B1 SA515361104 B1 SA 515361104B1 SA 515361104 A SA515361104 A SA 515361104A SA 515361104 A SA515361104 A SA 515361104A SA 515361104 B1 SA515361104 B1 SA 515361104B1
Authority
SA
Saudi Arabia
Prior art keywords
hydroxyacetamide
hydroxypropyl
methylphenoxy
ethyl
diseases
Prior art date
Application number
SA515361104A
Other languages
Arabic (ar)
English (en)
Inventor
مارتين بولى،
بيات ستينر،
كيريل ليسكوب،
اوليفر نايلر،
Original Assignee
اكتيليون فارماسوتيكالز ال تي دي
ايدورسيا فارماسوتيكالز ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اكتيليون فارماسوتيكالز ال تي دي, ايدورسيا فارماسوتيكالز ليمتد filed Critical اكتيليون فارماسوتيكالز ال تي دي
Publication of SA515361104B1 publication Critical patent/SA515361104B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SA515361104A 2013-03-15 2015-09-14 مشتقات بيريدين-4-يل SA515361104B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
SA515361104B1 true SA515361104B1 (ar) 2016-06-28

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
SA515361104A SA515361104B1 (ar) 2013-03-15 2015-09-14 مشتقات بيريدين-4-يل

Country Status (33)

Country Link
US (1) US9617250B2 (OSRAM)
EP (1) EP2970236B1 (OSRAM)
JP (1) JP6387361B2 (OSRAM)
KR (1) KR102212975B1 (OSRAM)
CN (1) CN105189487B (OSRAM)
AR (1) AR095523A1 (OSRAM)
AU (1) AU2014229217B2 (OSRAM)
BR (1) BR112015023161B1 (OSRAM)
CA (1) CA2900910C (OSRAM)
CL (1) CL2015002620A1 (OSRAM)
CY (1) CY1119619T1 (OSRAM)
DK (1) DK2970236T3 (OSRAM)
EA (1) EA029309B1 (OSRAM)
ES (1) ES2649475T3 (OSRAM)
HR (1) HRP20171763T1 (OSRAM)
HU (1) HUE035154T2 (OSRAM)
IL (1) IL241363B (OSRAM)
LT (1) LT2970236T (OSRAM)
MA (1) MA38482B1 (OSRAM)
MX (1) MX363545B (OSRAM)
MY (1) MY173573A (OSRAM)
NO (1) NO2970236T3 (OSRAM)
NZ (1) NZ713080A (OSRAM)
PH (1) PH12015502118A1 (OSRAM)
PL (1) PL2970236T3 (OSRAM)
PT (1) PT2970236T (OSRAM)
SA (1) SA515361104B1 (OSRAM)
SG (1) SG11201507227UA (OSRAM)
SI (1) SI2970236T1 (OSRAM)
TW (1) TWI623534B (OSRAM)
UA (1) UA115357C2 (OSRAM)
WO (1) WO2014141171A1 (OSRAM)
ZA (1) ZA201507657B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド S1p1/edg1受容体アゴニストとしてのアミノ−ピリジン誘導体
PL2195311T3 (pl) 2007-08-17 2011-08-31 Actelion Pharmaceuticals Ltd Pochodne pirydynowe jako modulatory receptora S1P1/EDG1
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
CA2714614A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
SI2252609T1 (sl) * 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
BRPI0910288A2 (pt) 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
HUE025984T2 (hu) * 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
AR075781A1 (es) 2009-03-03 2011-04-27 Merck Serono Sa Derivados de oxadiazol piridina como agonistas del receptor s1p1/edg1 y un metodo para su preparacion.
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
SG191742A1 (en) 2011-01-19 2013-08-30 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives

Also Published As

Publication number Publication date
WO2014141171A1 (en) 2014-09-18
TWI623534B (zh) 2018-05-11
AU2014229217A1 (en) 2015-11-05
CN105189487B (zh) 2017-12-26
CY1119619T1 (el) 2018-04-04
BR112015023161A2 (pt) 2017-07-18
EP2970236B1 (en) 2017-08-30
JP6387361B2 (ja) 2018-09-05
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
SI2970236T1 (sl) 2017-11-30
CN105189487A (zh) 2015-12-23
EA029309B1 (ru) 2018-03-30
MX363545B (es) 2019-03-27
DK2970236T3 (en) 2017-10-16
CL2015002620A1 (es) 2016-03-18
BR112015023161A8 (pt) 2021-06-22
CA2900910C (en) 2021-03-30
IL241363B (en) 2018-11-29
MY173573A (en) 2020-02-04
AU2014229217B2 (en) 2017-12-14
KR102212975B1 (ko) 2021-02-05
BR112015023161B1 (pt) 2022-11-16
PL2970236T3 (pl) 2018-01-31
KR20150128947A (ko) 2015-11-18
JP2016512227A (ja) 2016-04-25
PT2970236T (pt) 2017-11-30
MA38482B1 (fr) 2018-11-30
AR095523A1 (es) 2015-10-21
LT2970236T (lt) 2017-11-10
EP2970236A1 (en) 2016-01-20
HUE035154T2 (en) 2018-05-02
PH12015502118A1 (en) 2016-01-25
HK1220454A1 (en) 2017-05-05
ZA201507657B (en) 2022-08-31
MX2015012293A (es) 2015-12-16
HRP20171763T1 (hr) 2017-12-29
IL241363A0 (en) 2015-11-30
ES2649475T3 (es) 2018-01-12
NZ713080A (en) 2020-06-26
TW201443044A (zh) 2014-11-16
MA38482A1 (fr) 2017-12-29
NO2970236T3 (OSRAM) 2018-01-27
US9617250B2 (en) 2017-04-11
SG11201507227UA (en) 2015-10-29
CA2900910A1 (en) 2014-09-18
UA115357C2 (uk) 2017-10-25
EA201500931A1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
JP6387361B2 (ja) ピリジン−4−イル誘導体
EP3712153B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JP5036923B1 (ja) ピリジン−4−イル誘導体
EP4332102A1 (en) Isoquinolone compound and use thereof
MXPA05002644A (es) Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
JP2009543836A (ja) インドール化合物
JP2009543838A (ja) インドール化合物
EP3846809A1 (en) 2,6-diamino pyridine compounds
JP2009543837A (ja) Ep1受容体に対して親和性を有するインドール化合物
EP2665720B1 (en) 2-methoxy-pyridin-4-yl derivatives
EA023238B1 (ru) Замещенные производные индола для лечения иммунологических расстройств
KR20220016223A (ko) Rip-1 키나아제 억제제인 바이사이클릭 화합물 및 이의 응용
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
WO2024012425A1 (zh) 作为ripk1抑制剂的杂环化合物
TW202411221A (zh) 一種三嗪二酮類衍生物的晶型及製備方法
CN120590460A (zh) Vhl类衍生物及其在制备smarca2降解剂中的用途
KR20150079665A (ko) 치환된 인돌 유도체
HK1220454B (en) Pyridin-4-yl derivatives
WO2010005385A1 (en) 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308
BR112018015501B1 (pt) Derivados de pirazolo[1,5-a]pirazin-4-ila como inibidores de jak, seu uso e composição farmacêutica que os compreende
HK1191645B (en) 2-methoxy-pyridin-4-yl derivatives